U.S. markets closed

Gritstone Oncology, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.10-0.13 (-1.41%)
At close: 4:00PM EDT

Gritstone Oncology, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
http://gritstoneoncology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees169

Key Executives

NameTitlePayExercisedYear Born
Dr. Andrew R. AllenCo-Founder, Pres, CEO, Interim Principal Financial Officer & Director792.27kN/A1967
Dr. Karin JoossHead of R&D570.87kN/A1966
Prof. Raphael F. Rousseau M.D., Ph.D.Exec. VP & Chief Medical Officer588.37kN/A1969
Mr. Erin E. Jones M.S.Chief Operating OfficerN/AN/A1973
Mr. James ChoChief Accounting OfficerN/AN/AN/A
Dr. Roman YelenskyExec. VP & CTON/AN/A1979
Mr. Rahsaan W. Thompson J.D.Exec. VP & Gen. CounselN/AN/A1972
Mr. Matthew HawrylukExec. VP & Chief Bus. OfficerN/AN/A1978
Mr. Vijay Yabannavar Ph.D.Exec. VP, Chief Manufacturing & Technical Operations OfficerN/AN/A1962
Mr. Alan C. Mendelson J.D.Sec.N/AN/A1950
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gritstone Oncology, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Corporate Governance

Gritstone Oncology, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 8. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.